Endocrine Oncology

177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence in Endocrine Oncology. By Kalyan Mansukhbhai Shekhda et al. Figure 1. Flow chart of inclusion process of study cohort. Endocrine Oncology 5, 1; 10.1530/EO-25-0019. Open Access. Society for Endocrinology. Published by Bioscientifica.

Cytoreductive surgery is standard for metastatic phaeochromocytomas & paragangliomas. 177Lu‑DOTATATE PRRT could offer a safe, effective option for inoperable cases.

Kalyan Mansukhbhai Shekhda et al. report encouraging PFS & improved health-related QoL following PRRT.

🔗 doi.org/10.1530/EO-25-0019

Cytologically non-malignant thyroid nodules with three or more high-risk genetic mutations have poor outcomes in Endocrine Oncology. By Alexander R Goldberg et al. Open Access Figure 1. Case 1 histology and molecular testing: tumor subpopulations with relative hypocellularity (T1), hypercellularity (T2), and an intermediate area (T3). Each section was further analyzed by molecular testing and compared to the sternal metastasis molecular testing. Endocrine Oncology 5, 1; 10.1530/EO-25-0054. Published by bioscientifica. Society for Endocrinology.

🔬 Molecular testing is changing how we assess thyroid cancer risk.

New research by Alexander R Goldberg et al. explores the clinical & molecular characteristics of cytologically non-malignant thyroid tumors with multiple high-risk mutations, revealing aggressive behaviour.

#ThyroidCancer

Macrophage abundance in oncocytic thyroid cancer is associated with PD-L1 expression in Endocrine Oncology. By Julio C Ricarte-Filho et al. Open Access. Published by Bioscientifica. Society for Endocrinology. Figure 1 (A) Volcano plot highlighting mRNAs differentially expressed between (OTCs, n = 12) and non-neoplastic thyroids (n = 9). The cyan dots denote downregulated gene expression in OTC, and the purple dots denote upregulated gene expression in OTC. Gray dots denote gene expression without significant differences (fold change ≥2 and FDR ≤0.05). (B) Top DEGs between OTC (blue) and non-neoplastic thyroids (yellow). Plots show top five upregulated genes (top) and downregulated genes (bottom) in oncocytic tumors. (C) Functional enrichment analysis of upregulated genes reveals enrichment for genes related to metabolic pathways (KEGG database), carbon metabolism, and others. (D) Heatmap displaying increased mRNA expression of metabolic genes in OTC vs non-neoplastic thyroids. Red: upregulated genes; blue: downregulated genes. FC: fold change. Citation: Endocrine Oncology 5, 1; 10.1530/EO-25-0026

🧬 New research by Julio Ricarte Filho et al. provides the first comprehensive molecular and immune comparison of oncocytic thyroid cancer and follicular thyroid cancer, offering new insights into their biological differences.

👉 Read the full research: doi.org/10.1530/EO-25-0026

Explore influential studies in endocrine-related cancers published in Endocrine Oncology, a society-owned journal, covering topics from prolactinomas to thyroid tumours 👉 eo.bioscientifica.com/page/top-cited/top-cited-articles

Endocrine Oncology is proudly endorsed by BACR.

68Ga-DOTA-TATE PET/CT improves accuracy and guides management in multiple endocrine neoplasia type 1 (MEN-1) patients with suspected duodeno-pancreatic neuroendocrine tumours in Endocrine Oncology. By Kalyan Vamshi Vemulapalli et al. Figure 1. (A) MRI abdomen: difficult to identify pancreatic lesion on MRI. (B) 68Ga-DOTA-TATE PET/CT avid pancreatic body lesion. Endocrine Oncology 5, 1; 10.1530/EO-25-0060 Published by Bioscientifica. Society for Endocrinology. Open Access.

New research by Kalyan Vamshi Vemulapalli et al. demonstrates that ⁶⁸Ga-DOTA-TATE PET/CT offers a higher detection rate for dpNETs in MEN1 patients compared to conventional CT and MRI - resulting in significant changes to clinical management.

📖 Read the full article: doi.org/10.1530/EO-25-0060

Efficacy of systemic therapy in metastatic adrenocortical carcinoma: a meta-analysis of prospective clinical trials in Endocrine Oncology. By S Shekar et al. Figure 2. Forest plot of pooled ORRs in metastatic adrenocortical carcinoma, stratified by treatment subgroup. Endocrine Oncology 5, 1; 10.1530/EO-25-0027 Published by bioscientifica. Society for Endocrinology.

Systemic therapy for metastatic adrenocortical carcinoma (mACC) remains a challenge.

A new meta-analysis by S Shekar et al. synthesises prospective trial data to:
💡 Benchmark survival and response
💡 Compare treatment efficacy
💡 Identify gaps for future trials

🔗 doi.org/10.1530/EO-25-0027

Register Now! 2025 Margie & Robert E. Petersen. Neuroendocrine Tumor Research Symposium. Breakthroughs today, cures tomorrow. Location: Boston, Massachusetts. Date: November 17-19.

Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19.

The NETRF Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.

Register now: bit.ly/4nQ9goU

#NETresearch #cancerresearch

Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas in Endocrine Oncology. By Eleni Armeni et al. Published by Bioscientifica. Society for Endocrinology. Figure 1: Third-line treatment: median values of PFS comparing PRRT vs other agents (molecular agents or chemotherapy). Endocrine Oncology 5, 1; 10.1530/EO-24-0083

🆕 A retrospective case series by Eleni Armeni et al. from Royal Free Hospital explores the diagnostic & therapeutic complexities of glucagonomas, offering a valuable reference point for clinicians & researchers navigating the field.

🔗Read the article: doi.org/10.1530/EO-24-0083

Follow us on LinkedIn. Endocrine Oncology. LinkedIn logo.

🌐 Endocrine Oncology has joined LinkedIn!

We're excited to connect with the global endocrine oncology community in a new space.

Follow us for the latest journal articles, special collections and key updates.

🌐 linkedin.com/company/endocrine-oncology/

Survival and prognostic differences between appendiceal NETs and goblet cell adenocarcinomas in Endocrine Oncology. By Kim Dijke et al. Figure 1. Kaplan–Meier curve for PFS in patients with aNET and aGCA. Citation: Endocrine Oncology 5, 1; 10.1530/EO-25-0028. Published by Bioscientifica. Society for Endocrinology. Open Access.

New research by Kim Dijke et al. (@nkinl.bsky.social) highlights the differences in disease course of appendiceal NETs & appendiceal goblet cell adenocarcinomas, supporting the exclusion of aGCAs from the group of NENs in the 5th #WHO classification.

Read the research: doi.org/10.1530/EO-25-0028

Special Collection: Pituitary Tumours: Scientific Discoveries, Clinical Advances and Contested Paradigms. Endocrine-Related Cancer. Collection Editors: Dr. Sunita M. C. De Sousa, MD, PhD Dr. Frederic Castinetti, MD, PhD Dr. Henriett Butz, MD, PhD Dr. Adrian F. Daly, MD, PhD

🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours!

We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.

📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc

Endocrine Oncology. Special Collection. Tumour Heterogeneity in Neuroendocrine Neoplasms. Open Access. Open for Submission. Guest Editors: Professor Louis de Mestier and Professor Jérôme Cros

🆕 Tumour Heterogeneity in Neuroendocrine Neoplasms Special Collection #NENs

We’re seeking cutting-edge research on the biological & clinical characterisation of NEN heterogeneity, highlighting its impact on prognosis & treatment outcomes.

🌐 More info: bit.ly/4lWsJTc
📢 Submit: eo@bioscientifica.com

Impact of single nucleotide variants in estrogen genes on ovarian cancer risk: a systematic review and meta-analysis in Endocrine Oncology. By M P Aguiar et al. Published by bioscientifica. Society for Endocrinology. Open Access.

🧬 A new systematic review and meta-analysis by M P Aguiar et al. links estrogen-related gene polymorphisms to ovarian cancer occurrence/susceptibility, uncovering variants in CYP17A1, COMT and GSTP1 that may be associated with risk.

🔗 Explore the review #OpenAccess: doi.org/10.1530/EO-25-0007

Follow us on LinkedIn. LinkedIn logo. Endocrine-Related Cancer logo.

🌱Endocrine-Related Cancer is officially on LinkedIn!

Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal.

🌐 linkedin.com/company/endocrine-related-cancer/

#MedSky #CancerResearch #EndocrineOncology #HormoneCancers

FAK inhibition disrupts tumor growth, apoptosis, and transcriptional regulation in GI-NETs in Endocrine Oncology. By Lara Toffoli et al. Open Access. Published by bioscientifica, Society for Endocrinology. Figure 6. Dual role of FAK in GI-NETs. Schematic model illustrating the dual role of FAK in gastrointestinal neuroendocrine tumors (GI-NETs). FAK regulates oncogenic pathways through both its kinase-dependent and scaffold (kinase-independent) functions. On the left, Y15 and PROTAC-FAK inhibit the kinase activity of FAK, leading to reduced ERK1/2 signaling and downstream suppression of RB1 transcription. On the right, PROTAC-FAK uniquely targets the scaffold function of FAK, which includes its nuclear translocation and putative interaction with histone acetyltransferases (HATs) or histone deacetylases (HDACs). This interaction may alter chromatin accessibility and modulate epigenetic control of RB1 expression, independent of classical phosphorylation signaling. This model supports a dual mechanism by which FAK promotes GI-NET cell survival and gene regulation. Created in BioRender. Gagliano T (2025) (https://BioRender.com/ddyjxrf). Endocrine Oncology 5, 1; 10.1530/EO-25-0052.

🔬 Latest research by Lara Toffoli et al. investigates the impact of FAK inhibition on GI neuroendocrine tumors (GI-NETs) demonstrating its pivotal role in pathogenesis of GI-NETs & supporting its therapeutic targeting.

👉 Read the full article: doi.org/10.1530/EO-2...

Your research can help advance hormone-dependent cancer treatment and improve patient care. Abstract submissions close Monday 15 Sept: bit.ly/4fqWdqL

Our study on FAK inhibition in GI-NETs reveals its dual role in tumor growth, invasion, and even epigenetic regulation.
Grateful to my team for their dedication, and to all colleagues, collaborators, and friends who supported us along the way. 🙏
📄 Open Access: eo.bioscientifica.com/view/journal...

💗 Proud of my young research group 💗
Despite limited resources and many challenges, we published our latest work in @endocrineoncology.bsky.social — an emerging journal with a distinguished editorial board of leading experts.
#CancerResearch #FAK #NeuroendocrineTumors #TeamScience

The Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs). Submissions Now Open. Proposal Due August 31, 2025. ERF Logo. NETRF logo.

Sponsored by @netrf.org, this $100,000 grant is designed to help an early-career, basic or clinical scientist conduct novel and innovative #NETs research.

Learn more: mierf.org/to-apply/

#neuroendocrinecancer #earlycareerresearcher

Epidemiological insights and survival patterns in neuroendocrine neoplasia: a geographic perspective in Endocrine Oncology. By Jessica Mangion, Josanne Vassallo, and Mark Gruppetta. Society of Endocrinology. Published by bioscientifica. Open Access. Figure 2: The global distribution of gastroenteropancreatic (GEP) NEN and lung NEN based on SIR. Endocrine Oncology 5, 1; 10.1530/EO-25-0039

📈Incidence & prevalence of neuroendocrine neoplasms continues to rise globally.

A new review by Jessica Mangion et al. explores global epidemiological data, reviewing trends & differences in incidence rates to improve our understanding of this rise.

🔗 doi.org/10.1530/EO-25-0039

Endocrine Oncology. Society of Endocrinology. Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours in Endocrine Oncology. By Isuru Gamage et al. Open Access, published by bioscientifica. Figure 1. Molecular imaging phenotype of insulinoma cases. Case 1 and case 2 both demonstrate a similar imaging phenotype, with the GaTate PET/CT demonstrating ≥ Krenning 3 (3 = higher than liver, 4 = higher than spleen) SSTR expression in hepatic metastatic disease. Some hepatic lesions also have mild-to-moderate FDG avidity. Case 1: primary pancreatic lesion denoted on GaTate maximum intensity projection (MIP) by orange arrow, with the remaining disease located in the liver. The moderate FDG uptake associated with the pancreatic primary is obscured by renal activity on the MIP. Axial panels demonstrate liver disease with Krenning 3–4 SSTR expression with mild-to-moderate FDG avidity. Case 2: post distal pancreatectomy and splenectomy. . No local pancreatic recurrence, multifocal hepatic metastatic disease. Axial panels demonstrate hepatic disease with Krenning 4 SSTR expression and a lesion with mild-to-moderate FDG avidity. Bilateral pleural effusions are seen on low-dose CT.

🔍Somatostatin analogues (SSA) can unmask insulinoma in presumed non-functional GEP-NETs.

A new case report by Isuru Gamage et al. (@petermaccc.bsky.social‬) presents two cases where SSA unmasked hypoglycaemia due to insulinoma.

📖 Check out the full report: doi.org/10.1530/EO-2...

New Research: Prevalence of growth hormone deficiency in brain tumor survivors: a systematic review and meta-analysis in Endocrine Oncology. Authors: Tatiana Tselovalnikova et al. Open Access. Published by Bioscientifica. Society for Endocrinology.

🧠A new systematic review and meta-analysis by Tatiana Tselovalnikova et al. highlights why long-term monitoring is crucial after cranial irradiation as growth hormone deficiency can develop years post-treatment.

👉Read the full article: doi.org/10.1530/EO-25-0025

Endocrine Oncology, New Research: Using routinely collected patient data to study the impact of type 2 diabetes on breast cancer. Figure 1 OS for all early cancer stages. Kaplan–Meier curves comparing survival of patients with stage 1, 2 or 3 breast cancer after surgery according to diabetes status. The curves show outcomes before propensity matching (A) and after propensity matching (B) for age, ethnicity, smoking status and BMI. The purple curve represents patients with T2DM and the green curve represents patients without T2DM.

Could type 2 diabetes mellitus influence breast cancer outcomes?

New research by Ayaan Khurshed et al. explores the impact of T2DM on localised breast cancer. 👉 Read the full article: doi.org/10.1530/EO-24-0039

#BreastCancer #Diabetes #OncologyResearch #T2DM

Endocrine Oncology. New Case Report. Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE. Figure 1. CT scan of patient 1. Endocrine Oncology 5, 1; 10.1530/EO-25-0033. Published by Bioscientifica. Society for Endocrinology. Open Access.

A new case report by Eleonora Pelle (moffittnews.bsky.social) explores three patients with mesenteric NETs, shedding light on the potential risk of bowel ischemia linked to ¹⁷⁷Lu-DOTATATE treatment.

📖Check out the full report #OpenAccess: doi.org/10.1530/EO-25-0033

Attending #ENDO2025? Come and visit the Bioscientifica booth, 803, to find out more about publishing in Endocrine Oncology! 🙌😄

Text reads: Open for Submissions. 24th ENS@T Scientific Meeting 2025. Special Collection. Prize for Best Paper. Bottom right: Endocrine Oncology logo.

Are you attending the 24th ENS@T Scientific Meeting?

In collaboration with ENS@T, we're inviting submissions from speakers and delegates to our new Special Collection dedicated to the important topics discussed at the meeting.

🔗 buff.ly/OOUSqHl

For queries or to submit: 📧 eo@bioscientifica.com

Left: Endocrine Oncology logo, text reads: Real-world lenvatinib use in metastatic thyroid cancer: early dose intensity and side effect profile in an Australian centre. By Monica Majumder et al. Published by Bioscientifica. Society for Endocrinology logo. Right: Image of Endocrine Oncology journal, with text in blue circle reading 'NEW RESEARCH'

🆕New real-world evidence from Monica Majumder et al. on #lenvatinib treatment in metastatic #ThyroidCancer emphasises the importance of supportive care to maximise early dose intensity and efficacy.

🔎Discover the full article: doi.org/10.1530/EO-2...

Endocrine Oncology Special Collection: Women in Neuroendocrine Tumour Science: Breaking Barriers and Building Legacies.

📣Call for submissions!

Be a part of our special collection celebrating the contributions and leadership of women in Neuroendocrine Tumour (NET) science.

Original research, reviews and case reports are all welcome.

📧Submit your proposal to: eo@bioscientifica.com📧

The latest review article in our Theranostics in Neuroendocrine Neoplasms special collection: 'Radioembolization for neuroendocrine tumors: procedure, application and clinical outcomes'.

Check out the latest review article in our Theranostics in Neuroendocrine Neoplasms special collection: 'Radioembolization for neuroendocrine tumors: procedure, application and clinical outcomes'.

By Li Shen Ho @umcutrecht.bsky.social et al.

🔗Read the full review article: doi.org/10.1530/EO-2...

📢Call for submissions!

We're inviting contributions to our special collection, Epidemiology & Genetics, focused on identifying trends in the evolving epidemiological and genetic landscape of endocrine-related tumours.

📨Submit your proposal to: eo@bioscientifica.com